Fig. 6
From: Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival

In vivo assay. A) Schematic subcutaneous tumor formation in BalbC NOD/SCID mice from tumoroids. (B) Tumor volumes of animals treated with MVC and/or CDDP were measured on day 21. (C) Time course of tumor formation in animals treated with MVC and/or CDDP. Mixed-effect analysis followed by Tukey’s multiple comparison test was used (*P ≤ 0.05, **P < 0.01). Data were expressed as mean ± SEM of three biological replicates) D) Survival chart of animals treated with MVC and/or CDDP. The Log-rank (Mantel-Cox) test was used to assess animal survival. The overlap of the survival curves for the control group, the group treated with MVC, and the group treated with the MVC/CDDP combination indicates that there were no deaths before euthanasia, in contrast to the group treated with CDDP alone. Values of P ≤ 0.05 were considered statistically significant. Maraviroc (MVC) and Cisplatin (CDDP)